Multifactorial attribution for vancomycin‐associated acute kidney injury
British Journal of Clinical Pharmacology · 2026
DOI: 10.1002/bcp.70592 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Yu-Ling Tseng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Vancomycin, Acute Kidney Injury, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Kaohsiung Veterans General Hospital.
Abstract (Originalsprache)
Aim
Vancomycin is a cornerstone therapy for severe gram‐positive infections but is known to cause acute kidney injury (AKI). Although AKI risk is concentration dependent, its heterogeneous nature in real‐world polypharmacy settings remains poorly understood. We assessed the association between vancomycin exposure and AKI while identifying heterogeneous risk patterns across patient subgroups.
Methods
We conducted a retrospective analysis of electronic health records of adults receiving vancomycin from 2019 to 2023 at a tertiary medical centre in southern Taiwan. Patients aged ≥20 years who received vancomycin for ≥3 consecutive days were included. The primary outcome was vancomycin‐associated AKI. The relationship between trough concentrations and AKI risk was analysed using logistic regression. Conditional average treatment effect (CATE) analysis using the X‐Learner framework estimated heterogeneous risk differences across subgroups by comorbidities and concomitant medications.
Results
Among 1611 patients (mean age 65.8 years), 374 (23.2%) developed AKI. Each 1 mg/L increase in trough concentration increased AKI odds by 8% (odds ratio 1.08; 95% confidence interval 1.06–1.10). Patients with high troughs (>15.5 mg/L) had a 31% higher absolute risk of AKI. The CATE analysis revealed substantial heterogeneity: Co‐administration of β‐lactams (piperacillin and meropenem) and loop diuretics increased vancomycin‐attributable AKI risk, with varying risk levels across subgroups.
Conclusion
The risk of vancomycin‐associated AKI varied across subgroups and was influenced by concomitant medications. Loop diuretics, piperacillin and meropenem affected the association between vancomycin exposure and AKI. These findings highlight the need for comprehensive risk assessment considering medication profiles and nephrotoxic potential, rather than vancomycin concentration alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
- Clinical Innovation and Research Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
- Department of Business Management, Institute of Health Care Management, National Sun Yat-Sen University, Kaohsiung, Taiwan.
- Department of Pharmacy, School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of Nursing, Shu-Zen Junior College of Medicine and Management, Kaohsiung, Taiwan.
ORCID-Profile: Chien-Chou Su, Yi-Chia Su
Förderung
- Kaohsiung Veterans General Hospital
Zitieren
APA
Tseng, Y. L., Su, C. C., Yang, C. S., Yin, C. H., & Su, Y. C. (2026). Multifactorial attribution for vancomycin‐associated acute kidney injury. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70592
Vancouver
Tseng YL, Su CC, Yang CS, Yin CH, Su YC. Multifactorial attribution for vancomycin‐associated acute kidney injury. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70592
BibTeX
@article{Tseng2026,
author = {Tseng, Yu-Ling and Su, Chien-Chou and Yang, Ching-Shiang and Yin, Chun-Hao and Su, Yi-Chia},
title = {Multifactorial attribution for vancomycin‐associated acute kidney injury},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70592}
}
EUVIMED